EISAI AND PIQUR SIGN LANDMARK COLLABORATION AGREEMENT TO INVESTIGATE HALAVEN® (ERIBULIN) AND PQR309 IN HARD TO TREAT FORM OF BREAST CANCER Agreement will see eribulin used in combination with novel PI3K mTOR inhibitor i - I Novel - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2016-02-17 03:09:52 Clinical medicine Medicine Cancer Antineoplastic drugs Cancer treatments Signal transduction Breast cancer Macrolides Eribulin Halichondrin B MTOR inhibitors Eisai		EISAI AND PIQUR SIGN LANDMARK COLLABORATION AGREEMENT TO INVESTIGATE HALAVEN® (ERIBULIN) AND PQR309 IN HARD TO TREAT FORM OF BREAST CANCER Agreement will see eribulin used in combination with novel PI3K/mTOR inhibitor i Add to Reading List Source URL: www.piqur.com Download Document from Source Website File Size: 86,70 KB Share Document on Facebook

	Hindawi Publishing Corporation Journal of Signal Transduction Volume 2012, Article ID, 14 pages doi:Review Article DocID: 1v3if - View Document
	Pathway Logic Pathway Logic Modeling of Protein Functional Domains in Signal Transduction DocID: 1uZZY - View Document
	Using Pathway Logic to Integrate Signal Transduction and Gene Expression Data 1 DocID: 1u0Kb - View Document
	The fat that feeds the fire: Understanding the pathogenesis of NASH and how it progresses to hepatocellular carcinoma Michael Karin Laboratory of Gene Regulation and Signal Transduction Departments of Pharmacology and Pa DocID: 1rEn9 - View Document
	Free Radical Biology and Medicine–301 Contents lists available at ScienceDirect Free Radical Biology and Medicine journal homepage: www.elsevier.com/locate/freeradbiomed DocID: 1rrvK - View Document